Study of the Safety, Tolerability, and Pharmacokinetics of Once Weekly Zicronapine in Patients With Schizophrenia

NCT01377233 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

46

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia

Interventions

DRUG: Zicronapine open-label lead-in 10 mg daily
DRUG: Zicronapine 10 mg daily
DRUG: Zicronapine 20 mg once weekly
DRUG: Zicronapine 30 mg once weekly
DRUG: Zicronapine 45 mg once weekly

Sponsor

H. Lundbeck A/S